Search BRITE hierarchies

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
  L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
    L01 ANTINEOPLASTIC AGENTS
      L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
        L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
          L01FD02 Pertuzumab
            D05446  Pertuzumab (USAN/INN) <JP/US>

USP drug classification [BR:br08302]
  Antineoplastics
    Monoclonal Antibody/Antibody-Drug Conjugate
      Pertuzumab
        D05446  Pertuzumab (USAN/INN)

Therapeutic category of drugs in Japan [BR:br08301]
  4  Agents affecting cellular function
    42  Antineoplastics
      429  Miscellaneous
        4291  Other Antitumors
          D05446  Pertuzumab (USAN/INN); Pertuzumab (genetical recombination) (JAN)

Drug groups [BR:br08330]
  Antineoplastic
    DG01918  Tyrosine kinase inhibitor
      DG01917  Receptor tyrosine kinase inhibitor
        DG03158  HER2 inhibitor
          D05446  Pertuzumab

Drug classes [BR:br08332]
  Antineoplastic
    DG03158  HER2 inhibitor
      D05446  Pertuzumab

Target-based classification of drugs [BR:br08310]
  Protein kinases
    Receptor tyrosine kinases (RTK)
      EGFR family
        ERBB2* (HER2, CD340) [HSA_VAR:2064v1 2064v3] [HSA:2064] [KO:K05083]
          D05446  Pertuzumab (USAN/INN) <JP/US>

New drug approvals in the USA [br08319.html]
  D05446

New drug approvals in Europe [br08329.html]
  D05446

New drug approvals in Japan [br08318.html]
  D05446

New drug approvals in the USA, Europe and Japan [br08328.html]
  D05446

Pharmacogenomic biomarkers [br08341.html]
  D05446